RIPK3 and neoplasm: For example, in 85% of breast cancer patients, the expression of RIPK3 in the tumor was reduced compared with that in normal tissues, and the restoration of RIPK3 expression with hypomethylation agents could promote sensitivity to chemotherapy drugs in a RIPK3-dependent manner and enhance the tumor-killing effect of some chemotherapy drugs.